Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: A comparative study

International Immunopharmacology

Volumn 6, Issue 11, 2006, Pages 1673-1681

  Edens, R Erik ^a   Dagtas, Selma ^a   Gilbert, Kathleen M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Anergy; HDAI; Histone deacetylase inhibitors; Tolerance

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR I; HISTONE DEACETYLASE INHIBITOR III; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; OXAMFLATIN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; DEACETYLATION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TH1 CELL;

ANIMALS; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CLONAL ANERGY; ENZYME INHIBITORS; HEMOCYANIN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; INTERFERON TYPE II; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; TH1 CELLS;

EID: 33748428027     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.07.001     Document Type: Article

References (36)

1. Fallarino F. The 2004 FASEB Summer Research Conference on Transplant Immunology: closer to the goal of transplant-specific tolerance. Am J Transplant 5 (2005) 3-7
2. Schroeder R.A., Marroquin C.E., and Kuo P.C. Tolerance and the "Holy Grail" of transplantation. J Surg Res 111 (2003) 109-119
3. Rossini A.A., Greiner D.L., and Mordes J.P. Induction of immunologic tolerance for transplantation. Physiol Rev 79 (1999) 99-141
4. Gilbert K.M., and Weigle W.O. Th1 cell anergy and blockade in G1a phase of the cell cycle. J Immunol 151 (1993) 1245-1254
5. Gilbert K.M., Boger S., and Fifer E.K. Butyric acid derivative induces allospecific T cell anergy and prevents graft-versus-host disease. Immunopharmacol Immunotoxicol 25 (2003) 13-27
6. Gilbert K.M., Wahid R., Fecher N.P., Freeman J.P., and Fifer E.K. Potential clinical use of butyric acid derivatives to induce antigen-specific T cell inactivation. J Pharmacol Exp Ther 294 (2000) 1146-1153
7. Jackson S.K., DeLoose A., and Gilbert K.M. Induction of anergy in Th1 cells associated with increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. J Immunol 166 (2001) 952-958
8. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1 (2001) 194-202
9. Jackson S.K., DeLoose A., and Gilbert K.M. The ability of antigen, but not interleukin-2, to promote n-butyrate-induced T helper 1 cell anergy is associated with increased expression and altered association patterns of cyclin-dependent kinase inhibitors. Immunology 106 (2002) 486-495
10. Deckert J., and Struhl K. Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol Cell Biol 21 (2001) 2726-2735
11. Gregory P.D., Wagner K., and Horz W. Histone acetylation and chromatin remodeling. Exp Cell Res 265 (2001) 195-202
12. Gray S.G., and Ekstrom T.J. The human histone deacetylase family. Exp Cell Res 262 (2001) 75-83
13. Fournel M., Trachy-Bourget M.C., Yan P.T., Kalita A., Bonfils C., Beaulieu C., et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 62 (2002) 4325-4330
14. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9 (2003) 3578-3588
15. Khan S.B., Maududi T., Barton K., Ayers J., and Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 125 (2004) 156-161
16. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23 (2003) 9418-9427
17. Reddy P., Maeda Y., Hotary K., Liu C., Reznikov L.L., Dinarello C.A., et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 101 (2004) 3921-3926
18. Bohmig G.A., Krieger P.M., Saemann M.D., Ullrich R., Karimi H., Wekerle T., et al. Stable prodrugs of n-butyric acid: suppression of T cell alloresponses in vitro and prolongation of heart allograft survival in a fully allogeneic rat strain combination. Transpl Immunol 7 (1999) 221-227
19. Candido E.P., Reeves R., and Davie J.R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14 (1978) 105-113
20. Tsuji N., Kobayashi M., Nagashima K., Wakisaka Y., and Koizumi K. A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo) 29 (1976) 1-6
21. Kim Y.B., Lee K.H., Sugita K., Yoshida M., and Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18 (1999) 2461-2470
22. Su G.H., Sohn T.A., Ryu B., and Kern S.E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 60 (2000) 3137-3142
23. Suzuki T., Ando T., Tsuchiya K., Fukazawa N., Saito A., Mariko Y., et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42 (1999) 3001-3003
24. Jung M., Brosch G., Kolle D., Scherf H., Gerhauser C., and Loidl P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem 42 (1999) 4669-4679
25. Gilbert K.M., Hoang K.D., and Weigle W.O. Th1 and Th2 clones differ in their response to a tolerogenic signal. J Immunol 144 (1990) 2063-2071
26. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 99 (2002) 2995-3000
27. Ehst B.D., Ingulli E., and Jenkins M.K. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. Am J Transplant 3 (2003) 1355-1362
28. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
29. Lu Q., Yang Y.T., Chen C.S., Davis M., Byrd J.C., Etherton M.R., et al. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem 47 (2004) 467-474
30. Moreira J.M., Scheipers P., and Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3 (2003) 30
31. Kishiro Y., Ueda K., Fujiwara M., and Yamamoto I. Butyrate enhances the in vitro anti-SRBC (sheep red blood cell) antibody responses in murine splenocytes. Jpn J Pharmacol 66 (1994) 369-376
32. Le Gros G.S., Herbert A.G., and Watson J.D. The effects of sodium butyrate on lymphokine production. Lymphokine Res 4 (1985) 221-227
33. Diakos C., Prieschl E.E., Saemann M., Novotny V., Bohmig G., Csonga R., et al. Novel mode of interference with nuclear factor of activated T-cells regulation in T-cells by the bacterial metabolite n-butyrate. J Biol Chem 277 (2002) 24243-24251
34. Gilbert K.M., Boger S.R., Price P., and Fifer E.K. T cell tolerance induced by histone deacetylase inhibitor is mediated by P21cip1. Immunopharmacol Immunotoxicol 27 (2005) 545-564
35. + T cells is mediated by cyclin-dependent kinase inhibitor p21Cip1 in preparation.
36. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102 (2005) 3697-3702